Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Other Accumulated Expenses (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed Other Accumulated Expenses for 10 consecutive years, with $52948.0 as the latest value for Q2 2024.

  • For Q2 2024, Other Accumulated Expenses rose 156.16% year-over-year to $52948.0; the TTM value through Jun 2024 reached $52948.0, up 156.16%, while the annual FY2022 figure was $42406.0, 53.06% down from the prior year.
  • Other Accumulated Expenses hit $52948.0 in Q2 2024 for Crescent Biopharma, up from $10832.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $260972.0 in Q3 2020 and bottomed at $10832.0 in Q1 2024.
  • Average Other Accumulated Expenses over 5 years is $106627.4, with a median of $90342.0 recorded in 2021.
  • On a YoY basis, Other Accumulated Expenses climbed as much as 156.16% in 2024 and fell as far as 80.37% in 2024.
  • Crescent Biopharma's Other Accumulated Expenses stood at $220469.0 in 2020, then tumbled by 59.02% to $90342.0 in 2021, then plummeted by 53.06% to $42406.0 in 2022, then crashed by 61.19% to $16457.0 in 2023, then surged by 221.74% to $52948.0 in 2024.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $52948.0, $10832.0, and $16457.0 for Q2 2024, Q1 2024, and Q3 2023 respectively.